Skip to content
Peptide research

Semaglutide

Also known as Ozempic · Wegovy · Rybelsus
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

A modified GLP-1 receptor agonist marketed for weight loss and type 2 diabetes. Human evidence is strong, with large trials backing weight loss, glycemic control, and cardiovascular benefits, though neuroprotective claims stay speculative. Main risk is GI side effects in many users, plus a boxed thyroid-tumor warning (animal studies) and contraindication in MEN 2 or medullary thyroid cancer history. FDA-approved; obtain only through a licensed prescriber.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Significant weight loss

    High

    Large randomized trial showed 14.9% body weight loss versus 2.4% with placebo.

  • Type 2 diabetes control

    High

    Multiple large trials showed HbA1c reductions of 1 to 1.8 percentage points versus placebo.

  • Cardiovascular risk reduction

    High

    Two large outcome trials showed roughly 20 to 26% fewer major cardiovascular events.

Evidence limits

Evidence Level
Level 1 — Strong

Over 40,000 participants across dozens of Phase 3 RCTs. Evidence supports weight loss, T2DM, CV risk reduction, CKD.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of medullary thyroid carcinoma (MTC)

    Absolute

    GLP-1 agonists caused thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.

  • Type 1 diabetes

    Absolute

    Not indicated for T1DM. Risk of diabetic ketoacidosis.

  • History of pancreatitis

    High

    GLP-1 agonists may increase pancreatitis risk. Use with extreme caution if prior pancreatitis.

  • Severe gastroparesis

    High

    Semaglutide slows gastric emptying. Can worsen severe gastroparesis significantly.

  • Severe renal impairment

    Moderate

    GI side effects (nausea, vomiting) may worsen dehydration and renal function.

General cautions

  • Pregnancy or planning pregnancy

    Absolute

    Discontinue at least 2 months before planned conception. Animal studies show fetal harm.

Risk summary(7)

Risks = level of concern: High · Moderate · Low · Theoretical

  • GI side effects: nausea (20-44%), vomiting, diarrhea, constipation

    High
  • Boxed warning: thyroid C-cell tumors in animal studies (human relevance unclear)

    Moderate
  • Pancreatitis risk (rare)

    Low
  • Gallbladder disease risk

    Moderate
  • Acute kidney injury (rare, usually from dehydration due to GI effects)

    Low
  • Diabetic retinopathy complications

    Moderate
  • Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.